Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 May 5;133(9):1132-1134.
doi: 10.1097/CM9.0000000000000790.

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol

Yan-Ming Zeng  1 , Xiao-Lei Xu  1 , Xiao-Qing He  1 , Sheng-Quan Tang  1 , Yao Li  1 , Yin-Qiu Huang  2 , Vijay Harypursat  1 , Yao-Kai Chen  1   2
Affiliations
Comparative Study

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol

Yan-Ming Zeng et al. Chin Med J (Engl). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Flow diagram of the study.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. National Health Commission of the People's Republic of China. Guidelines for Diagnosis and Treatment of Novel Coronavirus Pneumonia (Trial Version 5) 2020. Available from: http://www.gov.cn/zhengce/zhengceku/2020-02/05/5474791/files/de44557832a.... [Accessed February 6, 2020] - PMC - PubMed
    1. Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir Ther 2016; 21:455–459. doi: 10.3851/IMP3002. - PubMed
    1. Spanakis N, Tsiodras S, Haagmans BL, Raj VS, Pontikis K, Koutsoukou A, et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents 2014; 44:528–532. doi: 10.1016/j.ijantimicag.2014.07.026. - PMC - PubMed
    1. Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Yin Z, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, China. J Med Microbiol 2003; 52:715–720. doi: 10.1099/jmm.0.05320-0. - PubMed
    1. So LY, Lau AC, Yam LY, Cheung TM, Poon E, Yung RW, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet (North American Edition) 2003; 361:0–1617. doi: 10.1016/S0140-6736(03)13265-5. - PMC - PubMed

Publication types